Mērķtiecīga prostatas vēža skrīninga programma – PSA laboratoriskās apstrādes pakalpojums

The Contracting Authority is procuring a targeted prostate cancer screening pathway with a focus on men at increased risk due to an inherited BRCA2 variant utilising the competitive provider selection process under the Health Care Services (Provider Selection Regime) Regulations 2023.<br/><br/>NHS England is seeking a provider to deliver a national Prostate Specific Antigen (PSA) Laboratory Processing and Virtual Screening Pathway Coordination service to support the Targeted Prostate Cancer Screening Programme for England.<br/><br/>The service will include PSA Sample logistics from the agreed collection handoff point, Sample receipt and accessioning, PSA processing and result authorisation, secure result transmission, consumables provision, Sample and pathway tracking, Failsafe management, Programme data and reporting, and Virtual Screening Pathway Coordination. The VSPC function will include coordination of MRI appointments following an above-threshold PSA result and coordination of biopsy/urology appointments following an actionable MRI result, within the Authority-approved pathway and responsibility arrangements.<br/><br/>The procurement does not include delivery of diagnostic MRI scanning or MRI reporting, biopsy procedures, urology treatment, BRCA digital decision-resource development, BRCA genetic testing or development of the national Programme IT system. Clinical delivery and acceptance of onward referrals remain with the relevant commissioned clinical providers.